Creating a better bioeconomy with innovative genome technologies.

OriCiro is a pioneer of cell-free genome technology, providing a powerful tool for research and development aimed at unlocking the possibility of synthetic biology. The company’s proprietary technology focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules aiming to replace conventional cell-based methodology by not only streamlining current research processes, but also widening the scope of genomics research significantly. The company also owns a suite of genome technologies, including the assembly of DNA fragments and genome editing. Synthetic biology, through which new medicines and useful proteins can be produced more efficiently by modified and/or synthesized genomes — is developing rapidly worldwide. OriCiro’s technologies have potential markets in a variety of industries including the pharmaceutical, diagnostic, industrial biotech, food, and agricultural sectors.

FOUNDED
2018

HEADQUARTERS
Tokyo, Japan

COMPANY SIZE
6–20

Seiji Hirasaki

Seiji Hirasaki (CEO at OriCiro) has been an Unreasonable Fellow since September 2019 and most recently participated in Unreasonable Impact Asia Pacific 2019.

Unreasonable Impact Asia Pacific 2019

Connect with OriCiro

Follow OriCiro on social media below.

  • Featured VentureOne Earth Designs

  • Featured Ventured.light